Jazz Pharmaceuticals plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JAZZ research report →
About the company
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.
- CEO
- Renee D. Gala
- IPO
- 2007
- Employees
- 2,890
- HQ
- Dublin, IE
Price Chart
- Market Cap
- $15.29B
- P/E
- 593.83
- P/S
- 3.45
- P/B
- 3.33
- EV/EBITDA
- 34.67
- Div Yield
- 0.00%
- Gross Margin
- 84.12%
- Op Margin
- 11.13%
- Net Margin
- 0.66%
- ROE
- 0.71%
- ROIC
- -0.62%
- Revenue
- $4.27B · 4.88%
- Net Income
- $-356,148,000 · -163.58%
- EPS
- $-5.84 · -164.46%
- Op Income
- $224.42M
- FCF YoY
- -14.97%
- 52W High
- $243.81
- 52W Low
- $105.00
- 50D MA
- $226.48
- 200D MA
- $179.78
- Beta
- 0.32
- Avg Volume
- 946.75K
Get TickerSpark's AI analysis on JAZZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Pearce Samantha | other | 2,527 |
| Jun 30, 26 | GALA RENEE D | other | 4,835 |
| Jun 30, 26 | Iannone Robert | other | 3,764 |
| Jun 30, 26 | Patil Neena M | other | 2,678 |
| Jun 30, 26 | Johnson Philip L | other | 3,343 |
| Jun 15, 26 | Smith Mark Douglas | sell | 1,157 |
| Jun 10, 26 | Patil Neena M | sell | 1,200 |
| Jun 3, 26 | GALA RENEE D | other | 600 |
| May 28, 26 | Patil Neena M | sell | 1,192 |
| May 28, 26 | Pearce Samantha | other | 6,907 |
Our JAZZ coverage
Recent articles, reports, and earnings notes.
No research on JAZZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JAZZ report →Similar companies
Peers in the same neighborhood.